Roche Pharmaceutical Development and Sales Overview
Diagnostics Division quarterly sales and CER growth¹
Roche
Q3 21
Q4 21
Reported
Q1 22
Restatement³
Q322
CHFm %CER CHFm %CER CHFm %CER CHFm %CER CHFm %CER
Q2 22
Q3 21
Q4 21
Q122 Q2 22 Q322
CHFm %CER CHFm %CER CHFm %CER CHFm %CER CHFm % CER
Core Lab²,3
1,884
12
1,863
10
1,873 8
1,961 1 1,938 7
Point of Care³
Molecular Lab³
Diabetes Care
Pathology Lab
442 143
525
-2
1,302 84
987
10
321 -19
617 222
1,907 12 1,883 9 1,896 8
719 15 1,466 84
1,979 1
1,958 7
1,143 15
477 -16
1,238
21
1,358
15
1,376
26
965
-13
931 -22
1,040
5
1,144
7
1,189
21
791
-20
755 -24
400 -7
396
-2
417
-7
415
-3
387 2
400
-7
396 -2
417
-7
415
-3
387 2
299 4
313
7
318
14
334 7
323
10
299
4
313
7
318
14
334
7
323 10
Diagnostics Div. 4,263 18
4,455
8 5,286
24
4,662
0 3,900
-4
4,263
18
4,455
8 5,286 24
4,662
0
3,900
-4
CER-Constant Exchange Rates; ' versus same period of prior year; 2 incl. Roche Information Solutions; 3 Sales in the Point of Care customer area include sales from the Liat business (POC molecular), and sales in the Core
Lab customer area include sales from the Life Science Alliances, both previously shown as part of Molecular Lab customer area. The comparative information for 2021 has been updated accordingly. In Q1 21 POC
molecular sales = 90mCHF, Q2 21=92mCHF, Q3 21=175mCHF, Q4 21-194mCHF. In Q1 21 LS Alliances = 21mCHF, Q2 21-23mCHF, Q3 21-23m CHF, Q4 21=20mCHF.
169View entire presentation